|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00570 TRAD CHI MED
Nominal 
1.950 -0.060 (-2.985%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 16,509,708 | -8.896% | 18,121,861 | 14,304,242 | 19,052,802 | 14,806,168 |
| Cost of Sales | (8,653,400) | -2.192% | (8,847,369) | (7,105,790) | (7,223,639) | (5,680,093) |
| Gross Profit | 7,856,308 | -15.291% | 9,274,492 | 7,198,452 | 11,829,163 | 9,126,075 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (106,554) | 1037.668% | (9,366) | (10,073) | (13,879) | (53,725) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (950) | -74.317% | (3,699) | (3,479) | (10,749) | (15,874) | |
| Profit / (Loss) before Taxation | 163,109 | -86.680% | 1,224,533 | 840,109 | 2,520,280 | 2,230,091 | |
| Taxation | (142,338) | -- | 171,537 | (119,144) | (396,856) | (369,447) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 33,296 | -- | (110,870) | 43,521 | (190,566) | (197,389) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 54,067 | -95.793% | 1,285,200 | 764,486 | 1,932,858 | 1,663,255 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 123,858 | -7.422% | 133,788 | 153,426 | 159,453 | 197,066 |
| Depreciation & Amortisation | 1,130,224 | -0.269% | 1,133,271 | 1,099,397 | 849,597 | 684,079 |
| Directors' Emoluments | 4,402 | -50.717% | 8,932 | 8,971 | 8,003 | 8,515 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 1.070 | -95.807% | 25.520 | 15.180 | 38.380 | 33.030 |
| DPS (cts) | 7.980 | -- | 0.000 | 4.550 | 11.520 | 0.000 |
| Dividend Payout Ratio (%) | 745.794% | -- | -- | 29.974% | 30.016% | -- |
| Cash flow per share ($) | -- | -- | 0.232 | 0.217 | 0.158 | 0.045 |
| NBV per share ($) | 4.211 | -- | 4.202 | 4.005 | 3.916 | 3.587 |
| Remarks: | Real time quote last updated: 31/03/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 54,067 |
| %Change | -95.793% |
| EPS / (LPS) | RMB 0.011 |
| NBV Per Share (¥) | RMB 4.211 |